Watch MGRX. Know when insiders buy.
One email the day a filing lands. Free.
MGRX
MANGOCEUTICALS, INC.
0.48
+0.03 +6.97%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.3MP/E —DIV YIELD —FCF YIELD —REV TTM $315K −38.9%NET INCOME −$15.1MNET CASH —52W 0.16 – 2.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $69K | −59.1% | 64.3% | −$1M | −$1.3M | — | -0.09 | −$261K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $68K | −37.9% | 42.7% | −$3.1M | −$3.4M | — | -0.22 | −$1.3M | — | — | May 19 |
| Q4 2025 · Dec 31derived | $94K | −10.3% | 50.3% | −$368K | −$2.8M | — | -0.01 | −$1.1M | — | — | Apr 1 |
| Q3 2025 · Sep 30 | $84K | −36.8% | 60.4% | −$7.5M | −$7.6M | — | -0.69 | −$1.2M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | $168K | +3.0% | 53.5% | −$5.3M | −$5.4M | — | -0.57 | −$1.3M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $109K | −48.9% | 56.8% | −$4.6M | −$4.8M | — | -1.12 | −$2.3M | — | — | May 19 |
| Q4 2024 · Dec 31derived | $105K | −56.9% | 76.1% | −$1.7M | −$1.9M | — | -0.52 | −$1.1M | — | — | Apr 1 |
| Q3 2024 · Sep 30 | $133K | −45.6% | 62.0% | −$1.8M | −$2M | — | -1.14 | −$1.2M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | $163K | — | 42.8% | −$2.2M | −$2.4M | — | -1.37 | −$1.6M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | $214K | — | 68.8% | −$2.4M | −$2.4M | — | -1.50 | −$991K | — | — | May 15 |
| Q4 2023 · Dec 31derived | $244K | — | 58.3% | −$2.6M | −$2.6M | — | -1.90 | −$1.7M | $0 | −$1.7M | Mar 20 |
| Q3 2023 · Sep 30 | $245K | — | 59.0% | −$1.8M | −$1.8M | — | -1.70 | −$1.7M | $0 | −$1.7M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $456K | 54.9% | −$18M | −$20.6M | -4526.8% | -2.17 | −$5.9M | — | — | — | — |
| FY2024 · to Dec 31 | $616K | 61.7% | −$8M | −$8.7M | -1413.6% | -4.80 | −$4.9M | — | — | — | — |
| FY2023 · to Dec 31 | $731K | 59.0% | −$9.2M | −$9.2M | -1259.4% | -8.58 | −$7M | $4K | −$7M | — | — |
| FY2022 · to Dec 31 | $9K | 54.3% | −$2M | −$2M | -22352.1% | -0.19 | −$1.3M | $43K | −$1.4M | — | — |
Every number comes from MANGOCEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.